Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Maria J G T Vehreschild,Emilio Bouza,Joop Van Oene,Simon D Goldenberg,Florian Thalhammer,Areti Georgopali,Graham Wetherill,Surabhi Taori

doi:10.1007/s10096-018-3410-8

Abstract

The article “Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)”, written by M.J.G.T. Vehreschild et al., was originally published at Springerlink on 11 August 2018 without open access.

Highlights

the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License
With the authors' decision to opt for Open Choice the copyright of the article changed on
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License

Summary

Introduction

With the authors’ decision to opt for Open Choice the copyright of the article changed on October 2018 to © The. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Results

Conclusion